​

Dyne Therapeutics Stock (NASDAQ:DYN)

ForecastOwnershipFinancialsChart
Dyne Therapeutics by TradingView

Previous Close

$7.85

52W Range

$6.36 - $47.45

50D Avg

$11.76

200D Avg

$26.97

Market Cap

$885.74M

Avg Vol (3M)

$2.23M

Beta

1.21

Div Yield

-

DYN Company Profile

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

191

IPO Date

Sep 17, 2020

Website

DYN Performance

DYN Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income$-343.89M$-242.16M$-170.96M
Net Income$-317.42M$-235.94M$-165.24M
EBITDA$-343.89M$-233.48M$-164.75M
Basic EPS$-3.37$-3.95$-3.18
Diluted EPS$-3.37$-3.95$-3.18

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q2 17Aug 04, 17 | 5:00 PM
Q1 17May 06, 17 | 5:00 PM
Q4 16Feb 24, 17 | 5:00 PM

Peer Comparison

TickerCompany
MLYSMineralys Therapeutics, Inc.
RVMDRevolution Medicines, Inc.
STOKStoke Therapeutics, Inc.
DSGNDesign Therapeutics, Inc.
PLRXPliant Therapeutics, Inc.
ERASErasca, Inc.
GLUEMonte Rosa Therapeutics, Inc.
EWTXEdgewise Therapeutics, Inc.
CYTKCytokinetics, Incorporated
CGEMCullinan Oncology, Inc.